Table 1.
Roles of ncRNAs in cancers drug resistance.
| Cancer types | Chemotherapeutic drugs | ncRNAs | Gene type | Alteration | Effect on Drug Resistance | Reference |
|---|---|---|---|---|---|---|
| OC | CDDP | miR-133a, miR-29c-3p, miR-30a LINC01125, LINC01508 circRNA Cdr1as |
Tumor suppressor | Downregulated | Sensitivity to CDDP | (45–50) |
| miR-181d, miR-149-3p lncRNA WDFY3-AS2, lncRNA CCAT1 circ-LPAR3, circHIPK2 |
Oncogene | Upregulated | Resistance to CDDP | (51–56) | ||
| PTX | miR-194-5p, hsa‐miR‐105 lncRNA SNHG5, lncRNA KB-1471A8.2 circEXOC6B |
Tumor suppressor | Downregulated | Sensitivity to PTX | (57–61) | |
| lncRNA SDHAP1, lncRNA HULC circ_0061140, circ_CELSR1 |
Oncogene | Upregulated | Resistance to PTX | (62–65) | ||
| GC | 5-FU | miR-204, miR195, exosomal miR-107 | Tumor suppressor | Downregulated | Sensitivity to 5-FU | (66–68) |
| miR-149 lncRNA HAGLR, lncRNA HNF1A-AS1 circRNA CPM, circNRIP1 |
Oncogene | Upregulated | Resistance to 5-FU | (69–73) | ||
| CDDP | microRNA-206 lncRNA ADAMTS9-AS2 circRNA MCTP2, circ_0001017 |
Tumor suppressor | Downregulated | Sensitivity to CDDP | (74–77) | |
| miR-193a-3p lncRNA BANCR, lncRNA MCM3AP-AS1 circRNA DONSON |
Oncogene | Upregulated | Resistance to CDDP | (78–81) | ||
| OXA | hsa_circ_0001546 | Tumor suppressor | Downregulated | Sensitivity to OXA | (82) | |
| lncRNA DDX11-AS1 circ_0032821 |
Oncogene | Upregulated | Resistance to OXA | (83, 84) | ||
| NSCLC | CDDP | miR-186-5p, miR-101-3p lncRNA SPRY4-IT1 circ_0030998 |
Tumor suppressor | Downregulated | Sensitivity to CDDP | (85–88) |
| microRNA-25-3p lncRNA SNHG1, LINC01224 circRNA_100565 |
Oncogene | Upregulated | Resistance to CDDP | (89–92) | ||
| CRC | 5-FU | miR-375-3p lncRNA HAND2-AS1, circDDX17 |
Tumor suppressor | Downregulated | Sensitivity to 5-FU | (93–95) |
| miR-29b-3p lncRNA LBX2-AS1 circ_0007031 |
Oncogene | Upregulated | Resistance to 5-FU | (96–98) | ||
| OXA | miR-200b-3p circ-FBXW7 |
Tumor suppressor | Downregulated | Sensitivity to OXA | (99, 100) | |
| miR-454-3p lncRNA CACS15 |
Oncogene | Upregulated | Resistance to OXA | (101, 102) | ||
| HCC | sorafenib | miR-138-1-3p, miRNA-124-3p.1 lncRNA FOXD2‐AS1 |
Tumor suppressor | Downregulated | Sensitivity to sorafenib | (103–105) |
| miR-126-3p lncRNA DANCR circFOXM1 |
Oncogene | Upregulated | Resistance to sorafenib | (106–108) | ||
| CDDP | miR-27a-3p lncRNA GAS5 |
Tumor suppressor | Downregulated | Sensitivity to CDDP | (109, 110) | |
| lncRNA FGD5-AS1 circMRPS35 |
Oncogene | Upregulated | Resistance to CDDP | (111, 112) | ||
| BC | ADR | miR-3609 circKDM4C |
Tumor suppressor | Downregulated | Sensitivity to ADR | (113, 114) |
| microRNA-221 lnc-LOC645166 circRNA_0044556 |
Oncogene | Upregulated | Resistance to ADR | (115–117) | ||
| tamoxifen | lncRNA ADAMTS9-AS2 hsa_circ_0025202 |
Tumor suppressor | Downregulated | Sensitivity to tamoxifen | (118, 119) | |
| miR-24-3p lncRNA CYTOR |
oncogene | Upregulated | Resistance to tamoxifen | (120, 121) | ||
| CC | CDDP | miR-144 | Tumor suppressor | Downregulated | Sensitivity to CDDP | (122) |
| lncRNA OTUD6B-AS1 | Oncogene | Upregulated | Resistance to CDDP | (123) | ||
| Prostate cancer | docetaxel | circFoxo3 | Tumor suppressor | Downregulated | Sensitivity to docetaxel | (124) |
| exosomal circ-XIAP | Oncogene | Upregulated | Resistance to docetaxel | (125) | ||
| PC | gemcitabine | miRNA-3662 circ_0092367 |
Tumor suppressor | Downregulated | Sensitivity to gemcitabine | (126, 127) |
| miR-93-5p lncRNA PVT1 circHIPK3 |
Oncogene | Upregulated | Resistance to gemcitabine | (128–130) | ||
| Bladder cancer | CDDP | exosomal LINC00355 circ_0058063 |
Oncogene | Upregulated | Resistance to CDDP | (131, 132) |
| Renal cancer | sunitinib | miR-130b circSNX6 |
Oncogene | Upregulated | Resistance to sunitinib | (133, 134) |